SRPT Earnings Prediction
The chart below shows how SRPT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, SRPT sees a +2.57% change in stock price 10 days leading up to the earnings, and a +5.38% change 10 days following the report. On the earnings day itself, the stock moves by +1.43%. This data can give you a slight idea of what to expect for the next quarter's release.
SRPT Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
658.41M
65.94%
40.94%
Gross Margin
79.81%
-9.99%
-0.54%
Operating Margin
24.56%
295.49%
417.05%
Net Margin
24.16%
109.90%
236.02%
EPS
1.32
200.00%
288.24%
No Data Available
SRPT Earnings Analysis
Sarepta Therapeutics Inc Corporation (SRPT.O) Earnings Conference Call
Positive
Project Moonshot Success: Sarepta achieved all goals laid out in Project Moonshot, including obtaining approval for ELEVIDYS, a transformative therapy for Duchenne patients.
Record Gene Therapy Launch: ELEVIDYS had the most successful launch of a gene therapy in history, with Q4 sales of $384 million, a 112% increase over the previous quarter.
Sustainable Profitability Achieved: Sarepta became sustainably profitable and cash flow positive in 2024, projecting over $16 billion in operating income by 2030.
Projected Revenue Growth: The company expects net product revenue for 2025 to be between $2.9 billion and $3.1 billion, representing a 70% growth over 2024.
PMO Franchise Growth: Sarepta's PMO franchise grew modestly year-over-year, achieving $254 million in Q4, despite the launch of ELEVIDYS.
LGMD Program Advancements: The company is advancing multiple LGMD programs, with plans to submit a BLA for SRP-9003 in 2025 and initiate several other studies.
siRNA Program Collaboration: Sarepta's collaboration with Arrowhead adds a broad platform of siRNA programs, enhancing their gene therapy pipeline.
Therapy's Transformative Potential: The EMBARK study for ELEVIDYS showed statistically significant improvements in patients, supporting the therapy's transformative potential.
Strong Development Pipeline: Sarepta has a strong pipeline with numerous programs in various stages of development across multiple disease areas, including neuromuscular and CNS indications.
Negative
Cost of Sales Surge: The company recorded a significant increase in cost of sales, which rose to approximately $132.3 million in Q4 2024 from $44.2 million in Q4 2023, indicating rising expenses associated with the production of ELEVIDYS.
R&D Expense Increase: R&D expenses increased slightly to $200 million in Q4 2024 from $195.5 million in Q4 2023, primarily due to higher manufacturing costs, suggesting ongoing financial pressure in research and development.
SG&A Expense Increase: SG&A expenses also saw a notable rise, reaching approximately $163.9 million in Q4 2024 compared to $131.7 million in Q4 2023, driven by increased professional services and personnel costs, which could impact profitability.
R&D and SG&A Expense Increase: The company anticipates combined non-GAAP R&D and SG&A expenses to be in the range of $1.2 billion to $1.3 billion for 2025, indicating a significant increase in operational costs that may affect future profitability.
Profitability Challenges Ahead: Despite achieving profitability in 2024, the company faces challenges in maintaining this status due to rising operational costs and the need for continued investment in R&D and commercialization efforts.
SRPT FAQs
How does SRPT typically perform around its earnings report dates?
Is Sarepta Therapeutics Inc (SRPT) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
SRPT Earning Call Sentiment
Sarepta Therapeutics, Inc. (SRPT) Q4 2024 Earnings Call Transcript
SRPT.O
0.94%Positive
The earnings call reveals strong financial performance with significant revenue growth and profitability, exceeding guidance. Management's confidence in future growth and profitability, along with optimistic guidance, boosts sentiment. However, the absence of a share repurchase program and some lack of clarity in management's responses temper enthusiasm slightly. Overall, the strong financial metrics and positive outlook suggest a positive stock price movement.
